Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT001 Dose Finding in COPD
NCT01350128Phase 2Completed
- Sponsor
- Pearl Therapeutics
- Start
- May 2011
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrrolate metered dose inhaler in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Pearl Therapeutics. Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve 0-12 hours at Day 7. Started May 2011; status: completed.
02
Drugs
glycopyrrolate metered dose inhaler
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01350128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350128.